Rona Therapeutics Marks Progress with Phase 1 Trial of INHBE siRNA for Obesity Treatment Rona Therapeutics has successfully completed the first cohort of its Phase 1 trial for RN3161, an siRNA targeting obesity. This development may change obesity treatment.

Rona Therapeutics Marks Progress with Phase 1 Trial of INHBE siRNA for Obesity Treatment #None #Rona_Therapeutics #RN3161 #INHBE

Rona Therapeutics Takes Significant Step in Obesity Treatment with Phase 1 Development of INHBE siRNA Rona Therapeutics completes the first cohort of its Phase 1 clinical study on RN3161, a promising siRNA aimed at treating obesity, showcasing initial safety and tolerability.

Rona Therapeutics Takes Significant Step in Obesity Treatment with Phase 1 Development of INHBE siRNA #USA #Santa_Barbara #Rona_Therapeutics #RN3161 #INHBE

Rona Therapeutics Takes a Major Step Forward in Obesity Treatment with Phase 1 Trial Completion Rona Therapeutics has successfully completed Cohort 1 of its Phase 1 clinical study for RN3161, targeting obesity through advanced RNA technology. Initial results are promising.

Rona Therapeutics Takes a Major Step Forward in Obesity Treatment with Phase 1 Trial Completion #USA #Santa_Barbara #Rona_Therapeutics #RN3161 #INHBE